The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies

Summary

The use of low-dose aspirin and heparinoids has improved the pregnancy outcome in obstetric antiphospholipid syndrome (APS). However, current treatment fails in 20–30 % of APS pregnancies, raising the need to explore other treatments to improve obstetrical outcome. Hydroxychloroquine (HCQ) is widely used in patients with autoimmune diseases, mainly systemic lupus erythematous (SLE), due to its anti-inflammatory, anti-aggregant and immune-regulatory properties. Evidence from in vitro and animal models suggests a potential protective effect of HCQ in obstetric APS. Pending the availability of prospective trials, we aimed to systematically review the available evidence and to assess the clinical judgment of a panel of experts regarding the use of HCQ in improving pregnancy outcome in women with anti-phospholipid antibodies (aPL). Clinical data on the ability of HCQ to improve pregnancy outcome in women with aPL are very limited in the available literature. Only one cohort study evaluating maternal and fetal outcome of pregnancy in patients with SLE who were exposed to HCQ was identified. Four of 14 (29 %) treated with HCQ patients had pregnancy failure, compared with six of 24 (25 %) of patients not treated with HCQ. However, the effect of HCQ was not adjusted for the use of other medications such as aspirin, heparins or steroids. Selected experts were contacted by e-mail and asked to review the summary of the evidence provided by the working group and to briefly answer each of the proposed questions. Overall, the panel of experts agreed that adding HCQ could be considered in selected cases or after failure of standard treatment with aspirin and a heparin agent. Specifically, the majority of experts considered adding HCQ in specific scenarios, such as women with previous thrombosis (either arterial and/or venous), and/or with previous ischaemic placenta-mediated complications. Prospective studies are necessary before the use of HCQ during pregnancy in women with aPL should be routinely recommended for clinical practice.

Keywords

Antiphospholipid antibodies - antiphospholipid syndrome - pregnancy

• References

• 1 Miyakis S, Lockshin MD, Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 04: 295-306.
• 2 Ruiz-Irastorza G, Crowther M, Branch W. et al. Antiphospholipid syndrome. Lancet 2010; 376: 1498-1509.
• 3 Bramham K, Thomas M, Nelson-Piercy C. et al. First-trimester low- dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. Blood 2011; 117: 6948-6951.
• 4 Mekinian A, Costedoat-Chalumeau N, Masseau A. et al. Obstetrical APS: Is there a place for hydroxychloroquine to improve the pregnancy outcome?. Autoimmun Rev 2015; 14: 23-29.
• 5 Mekinian A, Lazzaroni MG, Kuzenko A. et al. The efficacy of hydroxychloro-quine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study. Autoimmun Rev 2015; 14: 498-502.
• 6 Ruiz-Irastorza G, Egurbide MV, Pijoan JI. et al. Effect of antimalarials on thrombosis and survival in patients with systemic 645 lupus erythematosus. Lupus 2006; 15: 577-583.
• 7 Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P. et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69: 20-28.
• 8 Shinjo SK, Bonfa E, Wojdyla D. et al. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum 2010; 62: 855-862.
• 9 Jancinova V, Nosal R, Petrikova M. On the inhibitory effect of chloroquine on blood platelet aggregation. Thromb Res 1994; 74: 495-504.
• 10 Pierangeli SS, Vega-Ostertag M, Harris EN. Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies. Thromb Res 2004; 114: 467-476.
• 11 Rand JH, Wu XX, Quinn AS. et al. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phos-pholipid bilayers. Blood 2008; 112: 1687-1695.
• 12 Ageno W, Dentali F, Squizzato A. et al. Evidence and clinical judgment: Treatment of cerebral vein thrombosis. Thromb Haemost 2010; 103: 1109-1115.
• 13 Kappa as a Measure of Concordance in Categorical Sorting. Available at: http://facultyvassaredu/lowry/kappahtml Accessed May 28, 2014.
• 14 Wilson WA, Gharavi AE, Koike T. et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheuma 1999; 42: 1309-1311.
• 15 Buchanan NM, Toubi E, Khamashta M. et al. Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. Ann Rheum Dis 1996; 55: 486-488.
• 16 Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69: 20-28.
• 17 van Tulder M, Furlan A, Bombardier C. et al. Editorial Board of the Cochrane Collaboration Back Review Group. Updated method guidelines for systematic reviews in the cochrane collaboration back review group. Spine 2003; 28: 1290-1299.